Market Place
Sourcing Support
Y-mAbs to Announce Q2 2025 Financial Results on August 8
07 Aug 2025 //
GLOBENEWSWIRE
SERB Pharmaceuticals Agrees to Acquire Y-mAbs Therapeutics
05 Aug 2025 //
GLOBENEWSWIRE
Y-mAbs Hosts Virtual Radiopharmaceutical R&D Update on Pipeline
28 May 2025 //
GLOBENEWSWIRE
Y-mAbs Reports Q1 2025 Financial Results and Corporate News
13 May 2025 //
GLOBENEWSWIRE
Y-mAbs Update NCCN Guidelines to Include Naxitamab-gqgk
07 May 2025 //
GLOBENEWSWIRE
Y-mAbs to Announce Q1 2025 Results on May 13, 2025
06 May 2025 //
GLOBENEWSWIRE
Y-mAbs Presents CD38-SADA Pharmacokinetics at 2025 AACR Meeting
27 Apr 2025 //
GLOBENEWSWIRE
Y-mAbs Starts Phase 1 Trial for CD38-SADA Radioimmunotherapy
25 Apr 2025 //
GLOBENEWSWIRE
Y-mAbs Reports Q4 2024 Financials, Corporate Updates
04 Mar 2025 //
GLOBENEWSWIRE
Y-mAbs Ph2 Interim Data Published In Nature Communications
03 Mar 2025 //
GLOBENEWSWIRE
Y-mAbs Sets March 4 For Q4, Full-Year 2024 Results
20 Feb 2025 //
GLOBENEWSWIRE
Y-mAbs Presents GD2-SADA Pharmacokinetics At SNMMI Annual Meeting
31 Jan 2025 //
GLOBENEWSWIRE
Y-mAbs Provides Strategic Business Update and 2025 Priorities
10 Jan 2025 //
GLOBENEWSWIRE
Y-mAbs Presents SADA Platform Preclinical Data at 2024 ASH Meeting
07 Dec 2024 //
GLOBENEWSWIRE
Y-mAbs to Participate at Citi’s 2024 Global Healthcare Conference
27 Nov 2024 //
GLOBENEWSWIRE
Y-mAbs & Nobelpharma License DANYELZA® for Japan
04 Nov 2024 //
GLOBENEWSWIRE
Y-mAbs Announces Third Quarter 2024 Conference Call and Webcast
25 Oct 2024 //
GLOBENEWSWIRE
Y-mAbs to Participate in Upcoming Investor Conferences in October
01 Oct 2024 //
GLOBENEWSWIRE
Y-mAbs: Preclinical GD2-SADA Data At SNMMI 2024
06 Jun 2024 //
GLOBENEWSWIRE
Y-mAbs` Naxitamab Shows New Phase 2 Interim Analysis At ASCO 2024
01 Jun 2024 //
GLOBENEWSWIRE
Y-mAbs Therapeutics Added to the NASDAQ Biotechnology Index
13 Dec 2023 //
GLOBENEWSWIRE
Y-mAbs Announces Presentation of Naxitamab Data at ASCO
26 May 2023 //
GLOBENEWSWIRE
Y-mAbs Announces Presentation of GD2-SADA Study at ASCO
26 May 2023 //
PRESS RELEASE
Y-mAbs DANYELZA for the Treatment of High-Risk Neuroblastoma approved in Brazil
23 May 2023 //
GLOBENEWSWIRE
Y-mAbs Announces Presentation of Naxitamab data at AACR
18 Apr 2023 //
GLOBENEWSWIRE
Y-mAbs Announces First Patient Dosed in Phase 1 Clinical Trial of GD2-SADA
05 Apr 2023 //
GLOBENEWSWIRE
Y-mAbs and EMA Reach Agreement on the Pediatric Investigation Plan for Naxitamab
02 Feb 2023 //
GLOBENEWSWIRE
